VANCOUVER, BC — August 5, 2026 — Leads & Copy — Shareholders of Lobe Sciences Ltd. have overwhelmingly approved all proposals presented at the company’s Annual General and Special Meeting of Shareholders, held on July 30, 2026. The approved matters included the election of directors, re-appointment of the auditor, a new Long-Term Incentive Plan, ratification of restricted share unit grants, and amendments to the company’s constating documents.
A total of 152,807,032 common shares, representing approximately 49.6% of the Company’s issued and outstanding common shares as of the June 15, 2026 record date, were represented at the meeting. All resolutions put forth to shareholders received strong support.
A significant resolution, the special resolution to amend the company’s constating documents, including the elimination of its existing class of preferred shares, passed with 99.773% shareholder approval. This move is intended to simplify the Company’s capital structure and enhance corporate governance transparency.
Shareholders also approved a new Long-Term Incentive Plan, which reduces the maximum number of common shares issuable under all security-based compensation arrangements from 40% to 20% of the Company’s issued and outstanding shares. This revised structure aims to better align management, employees, consultants, and directors with long-term shareholder interests while reducing potential dilution.
The following individuals were elected as directors to serve until the next annual meeting: Dr. Frederick D. Sancilio, Dr. Harry R. Jacobson, Wesley Ramjeet, Marco Mastrodonato, and Nick Karakochuk.
Following the formal business, management provided shareholders with an update on strategic, operational, and capital markets initiatives. Dr. Frederick D. Sancilio, Chairman and Chief Executive Officer, reviewed the company’s strategy of advancing therapeutic candidates through dedicated subsidiary companies. The objective is to progress these programs through value-creating development milestones and strategic initiatives designed to maximize shareholder value.
Management also discussed ongoing efforts toward a future senior exchange listing, which the Company believes could provide broader access to institutional investors, increase market visibility, enhance trading liquidity, and support future growth.
Updates were provided on the progress of the Company’s subsidiary development programs. Cynaptec Pharmaceuticals’ L-130 program, targeting chronic cluster headache with a patented oral new chemical entity designed as a stabilized form of psilocin, is advancing through preclinical development in support of a planned Investigational New Drug (IND) application with the U.S. Food and Drug Administration. Cynaptec Pharmaceuticals is a Lobe Sciences subsidiary focused on neurological and neuropsychiatric disorders, with Lobe Sciences owning approximately 64%.
Applied Lipid Therapeutics, a wholly owned subsidiary, is focused on developing lipid-based therapies for serious diseases. Its lead candidate, S-100, is being developed for sickle cell disease using a proprietary lipid delivery platform. Chemistry, manufacturing, and controls (CMC) activities are underway to support future clinical development, and an application for Orphan Drug Designation has been submitted to the U.S. Food and Drug Administration.
Lobe Sciences Ltd. is a biopharmaceutical development company focused on identifying, acquiring, developing, and advancing therapeutic candidates through specialized subsidiary platforms, including Cynaptec Pharmaceuticals and Applied Lipid Therapeutics.
Source: Lobe Sciences Ltd.
